← Eichor
Study identifier: NCT06280742 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)

Condition: Multiple Sclerosis  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants41
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The Service Hospitalier Frédéric-Joliot (SHFJ) and Paris Brain Institute (ICM) groups have identified \[18F\]-DPA-714 as a promising second-generation TSPO tracer, a macromolecule overexpressed in neuroinflammatory conditions, for PET imaging. They have also developed a non-invasive quantification methodology, enabling the generation of individual neuroinflammation maps in MS patients. Recent findings from \[18F\]-DPA-714 PET imaging in MS patients revealed that most of the white matter lesions contained a smoldering component, even when considered inactive on MRI, and that their neuroinflammatory profiles were associated with longitudinal disability worsening. The Inflanet project aims to leverage a unique consortium comprising French radiochemists, radiopharmacists, nuclear medicine/neuroimaging experts, and MS neurologists to establish the first national network dedicated to \[18F\]-DPA-714 PET imaging in MS, so far limited to monocentric studies. The objectives of the INFLANET project are (1) to conduct the first multicenter study assessing neuroinflammation in patients with active MS using \[18F\]DPA-714 PET tracer, and (2) to establish a methodology suitable for the quantification of multicenter PET data obtained with \[18F\]DPA-714. The INFLANET initiative aims to disseminate TSPO PET within the French MS research community, thereby opening the unique perspective of future large-scale, multicenter studies. These endeavors are expected to enhance our capacity to predic…

This description comes directly from the study's public registry record.

Talk to the study team

Bruno Stankoff, MD  ·  0171970659  ·  bruno.stankoff@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (7)

Département de Neurologie,Pierre Wertheimer Neurological HospitalLyon, FranceRecruiting
CERMEPLyon, FranceRecruiting
CIC Neurosciences, GH Pitié-SalpêtrièreParis, FranceRecruiting
Centre Eugène MarquisRennes, FranceNot Yet Recruiting
Service de Neurologie, CHU PontchaillouRennes, FranceNot Yet Recruiting
CHU Toulouse - Département de NeurologieToulouse, FranceNot Yet Recruiting
CHU Toulouse - Service de médecine nucléaireToulouse, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06280742